Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 22Unspecified Adult Solid Tumor, Protocol Specific 3Prostatic Neoplasms 3Colonic Neoplasms 3Carcinoma, Ovarian Epithelial 3Breast Neoplasms, Male 3Rectal Neoplasms 2Ovarian Neoplasms 2Lung Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urogenital Neoplasms 1Stomach Neoplasms 1Sarcoma 1Prostatic Diseases 1Pancreatic Neoplasms 1Pain 1Non-squamous Non-small Cell Lung Cancer 1Neoplasms, Glandular and Epithelial 1Neoplasm Metastasis 1Liver Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Genital Neoplasms, Male 1Genital Diseases, Male 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Carcinoma 1Breast Cancer Organoids 1

Interventions

ixabepilone 1Standard of Care 1Practice Guidelines as Topic 1Epothilones 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Bilateral Breast Carcinoma × ixabepilone × Clear all
NCT00877500 2026-05-22

Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy

M.D. Anderson Cancer Center

Phase 2 Active not recruiting
116 enrolled
Breast

Bilateral Breast Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡